img 614-636-4850
  • Follow us:
Home > Board of Directors


Derrell D. Porter, M.D. - Dr. Porter is currently SVP, head of Commercial at Atara Biotherapeutics, Inc. Prior to joining Atara, he was a Vice President with Gilead Sciences, where he was responsible for corporate strategy, long term commercial planning, and global launch preparation for pipeline compounds in all of Gilead’s therapeutic areas – Oncology, HIV, Liver Diseases (HCV, HBV, and NASH), CV, and Inflammatory Disorders. With a successful biopharmaceutical career spanning 15+ years, Dr. Porter is a seasoned executive with experience running businesses in the US and Europe, corporate development and global marketing, as well as management consulting, including AbbVie and Amgen. He began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. Dr. Porter holds an MD from the University of Pennsylvania, where he was a Twenty First Century Scholar, an MBA from The Wharton School and a bachelor’s degree in neuroscience from UCLA.

Doug Poling - Mr. Poling is a private investor with a financial and legal background. Previously, he served as Executive Vice President of AIG Financial Products Corp. with responsibility for three business units comprising energy and infrastructure principal investments, tax enhanced structured finance and US corporate marketing. Before moving to the business side, Doug served as General Counsel and Chief Administrative Officer of AIG-FP for many years. He is a graduate of Tufts University (BA) and Yale Law School (JD).

Henry Cialone Ph.D. - Dr. Cialone is the President and CEO of Edison Welding Institute and has a record of creating new business opportunities through technological innovation. Prior to joining EWI in 2005, he was an executive at Battelle Memorial Institute, where he helped develop and manage a considerable alternative energy portfolio, ultimately leading the commercial energy business and serving on the governing board of the National Renewable Energy Laboratory. He received a PhD, MS and BS in materials science and engineering from Brown University.

Robert Kamerschen - Mr. Kamerschen is a private investor, senior advisor/consultant/mentor and retired senior executive across numerous diverse industries bringing extensive change agent and entrepreneurial experiences. Mr. Kamerschen was the Chairman of Survey Sampling Inc., a private company which provides internet and telephone survey sampling to marketing research companies, from June 2005 until his retirement in 2009. He is the Retired Chairman and Chief Executive Officer of ADVO, Inc., a NYSE-listed direct mail micro-targeting service company, which he led from 1988 until his retirement in 1999 having generated a 13-fold increase in shareholder value during his leadership tenure. His senior leadership roles include companies such as Scott Paper, Dunkin’ Donuts, Revlon, Chanel, Six Flags, Max Factor, Norton Simon and MCA. Mr. Kamerschen has served as an independent director with lead director or committee chairmanship status with 16 public companies, including IMS Health, R.R. Donnelley Corporation, Linens ‘n Things, Vertrue, Inc., Playboy Enterprises, and Radio Shack Corporation. He has also served on 25 private company boards, including 6 currently, backed primarily by private equity and venture capital companies. Mr. Kamerschen brings extensive management and corporate governance experience to the Board through his service in senior leadership positions in a number of public and private companies in diverse industry categories, including expertise in the advertising and marketing sector. Mr. Kamerschen retired in June 2014 as a Board Director at MDC Partners (MDCA-TSX) where he served for 12 years in various leadership roles; specifically Presiding Director as well as Chairman of the Human Resources & Compensation as well as the Nominating & Governance Committees. He remains as a significant shareholder in MDC Partners.

Ronald Moss, M.D. - Dr. Moss served as Chief Executive Officer of Ansun from October 2012 to February 2017, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology.

Ross O. Youngs, Founder and Chairman - Mr. Youngs has over 30 years of inventing products, technologies and processes for a variety of industries. Mr. Youngs holds over 75 patents worldwide and is driven to innovate by a focus on better, faster and less expensive. Recent major innovations have included an R&D 100 Award for collaboration on biopolymer technologies. In 2009, the Company was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology which helped lead to the development of Biosortia’s drug discovery platform. In 1998, Mr. Youngs was awarded the Ernst & Young Ohio Entrepreneur of the Year award and the U.S. Small Business Administration honored Mr. Youngs as their national “Business Person of the Year” in a presentation made by Vice President Al Gore.

Pin It on Pinterest